EGFR and non-small cell lung carcinoma: This article outlined the case of a NSCLC patient with brain and leptomeningeal metastases, harboring EGFR and somatic BRCA2 mutations, who developed resistance to the third-generation EGFR-TKIs but nonetheless demonstrated a lasting positive response to Olaparib.